Cargando…

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer

Detalles Bibliográficos
Autores principales: Majumdar, Swaratika, Noronha, Vanita, Joshi, Amit, Patil, Vijay, Kumar, Rajiv, Trivedi, Vaibhavi, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069325/
https://www.ncbi.nlm.nih.gov/pubmed/30112339
http://dx.doi.org/10.4103/sajc.sajc_199_18
_version_ 1783343466645815296
author Majumdar, Swaratika
Noronha, Vanita
Joshi, Amit
Patil, Vijay
Kumar, Rajiv
Trivedi, Vaibhavi
Prabhash, Kumar
author_facet Majumdar, Swaratika
Noronha, Vanita
Joshi, Amit
Patil, Vijay
Kumar, Rajiv
Trivedi, Vaibhavi
Prabhash, Kumar
author_sort Majumdar, Swaratika
collection PubMed
description
format Online
Article
Text
id pubmed-6069325
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-60693252018-08-15 Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer Majumdar, Swaratika Noronha, Vanita Joshi, Amit Patil, Vijay Kumar, Rajiv Trivedi, Vaibhavi Prabhash, Kumar South Asian J Cancer Letter to the Editor Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6069325/ /pubmed/30112339 http://dx.doi.org/10.4103/sajc.sajc_199_18 Text en Copyright: © 2018 The South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Letter to the Editor
Majumdar, Swaratika
Noronha, Vanita
Joshi, Amit
Patil, Vijay
Kumar, Rajiv
Trivedi, Vaibhavi
Prabhash, Kumar
Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
title Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
title_full Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
title_fullStr Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
title_full_unstemmed Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
title_short Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
title_sort sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069325/
https://www.ncbi.nlm.nih.gov/pubmed/30112339
http://dx.doi.org/10.4103/sajc.sajc_199_18
work_keys_str_mv AT majumdarswaratika sequentialtreatmentwithalectinibincrizotinibresistantnonsmallcelllungcancer
AT noronhavanita sequentialtreatmentwithalectinibincrizotinibresistantnonsmallcelllungcancer
AT joshiamit sequentialtreatmentwithalectinibincrizotinibresistantnonsmallcelllungcancer
AT patilvijay sequentialtreatmentwithalectinibincrizotinibresistantnonsmallcelllungcancer
AT kumarrajiv sequentialtreatmentwithalectinibincrizotinibresistantnonsmallcelllungcancer
AT trivedivaibhavi sequentialtreatmentwithalectinibincrizotinibresistantnonsmallcelllungcancer
AT prabhashkumar sequentialtreatmentwithalectinibincrizotinibresistantnonsmallcelllungcancer